Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 4/20 | 0.46 |
| ▸ | FLT4 | P35916 | 4/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 7/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409213 | 1.00 | AR (0.48) | ARNFE2L2MAPTPOLBGAA | |
| SCHEMBL4618131 | 0.89 | FLT1 (0.55) | NFE2L2MAPTRECQLFLT1FLT4 | |
| SCHEMBL4618139 | 0.89 | FLT1 (0.55) | NFE2L2MAPTRECQLFLT1FLT4 | |
| SCHEMBL5416384 | 0.88 | AR (0.49) | ARNFE2L2MAPTFLT1FLT4 | |
| SCHEMBL5416377 | 0.88 | AR (0.49) | ARNFE2L2MAPTFLT1FLT4 | |
| SCHEMBL5416933 | 0.88 | PTGES2 (0.53) | ARNFE2L2FLT1FLT4KDR | |
| SCHEMBL5416926 | 0.88 | PTGES2 (0.53) | ARNFE2L2FLT1FLT4KDR | |
| SCHEMBL4619056 | 0.87 | FLT1 (0.52) | NFE2L2MAPTFLT1FLT4KDR | |
| SCHEMBL4619064 | 0.87 | FLT1 (0.52) | NFE2L2MAPTFLT1FLT4KDR | |
| SCHEMBL5414746 | 0.82 | PTGES2 (0.47) | ARNFE2L2MAPTPTGES2LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | claimed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270874-A1 | Styrylsulfonamides | STS, SULT1E1, BRCA1 | AR 1575/4885NFE2L2 1842/4885MAPT 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.